An active medical device means any medical device relying for its functioning on a source of electrical energy or any source of power other than that directly generated by the human body or gravity. There is an increasing use of implantable cardiac devices in patients with chronic heart failure. These devices have a number of functions including pacing, defibrillation, and data collection. In addition, new generations of investigational stand-alone implantable hemodynamic monitoring systems are making their way toward clinical practice. “Meticulous Research” in its latest publication states that, the “global market for Active Implantable Devices Market is expected to grow at a CAGR of 6.7% from 2017 to 2022 to reach $24,024.0 million by 2022.”
This growth is primarily driven by the increasing burden of cardiovascular diseases, rising prevalence of neurological disorders, growing investments & funds to develop technologically advanced products, and expanded applications of neurostimulators.
American Heart Association (AHA) supports $3.3 billion for National Heart, Lung, and Blood Institute (NHLBI) in 2016. This funding will sustain current activities and investment in promising and critically needed scientific opportunities that will aggressively advance the fight against heart disease. The AHA recommends $1.8 billion for National Institute of Neurological Disorders and Stroke (NINDS) in 2016. This funding level will enhance existing initiatives and proactively advance the top priorities in stroke prevention, treatment and recovery research identified to address stroke, the fifth killer and a major cause of disability in the U.S. American Heart Association advocates for $33 billion for National Institutes of Health (NIH) to begin to restore its purchasing power.
Over the past decade, the NIH budget has not kept pace with medical research inflation, resulting in nearly a 25% loss in purchasing power. This funding level will allow NIH to capitalize on investments to improve health, spur economic growth, spark innovation, and preserve the U.S. leadership in medical research. The NIH continues to invest only 4% of its budget on heart research and a mere 1% on stroke research—America’s No. 1 and No.5 killers, respectively. These funding levels are not commensurate with research opportunities, the number afflicted, and the economic toll. Heart disease, stroke and other forms of cardiovascular disease remain No. 1 and most expensive killer, costing nearly $1 billion a day.
The AHA advocates for $130.037 million for CDC’s Division for Heart Disease and Stroke Prevention. This amount is identical to the FY 2014 and FY 2015 appropriations and the FY 2016 President’s budget. In FY 2014, CDC spent an average only 56 cents a person on heart disease and stroke prevention. An appropriation of this amount will allow the Division to enhance projects within State Public Health Actions (1305) and intensify efforts within the complimentary State and Local Public Health Actions to Prevent Obesity, Diabetes, and Heart Disease and Stroke (1422). It will maintain support for the Paul Coverdell National Acute Stroke Registry and Sodium Reduction in Communities, boost capacity for national, state and local heart disease and stroke surveillance, and provide aid for research and program evaluation. The AHA asks for $5 million for the Prevention and Public Health Fund for Million Hearts, a public-private initiative to prevent 1 million heart attacks and strokes by 2017. This funding will allow CDC to enhance efforts to prevent, detect, treat and control high blood pressure, a major cause of heart disease and stroke. In addition, the leading players in the active implantable devices market are continuously increasing their investment and R&D activities to develop innovative products to fulfill the unmet need in the area of chronic cardiovascular & neurological disorders.
For instance, the top ten players profiled in this study have received regulatory approvals for around 65 new & innovative products during the period of 2014-2017. The products launched in this duration have registered several advancements in active implantable devices including extended battery life of implantable cardioverter defibrillator (ICD), improvements in patient monitoring to avoid needless shocks, introduction of quadripolar lead devices to improve device programming, and development of magnetic resonance imaging (MRI)-safe ICDs. One of the biggest innovations has been the introduction of quadripolar lead devices. The leads use four electrodes to allow more programming options for pacing and overcoming issues with lead placement.
This can help optimize CRT-D therapy and decrease the number of patients not responding to the therapy. Similar ongoing innovations with rising investment & research by public & private sector, and leading players are expected to increase the adoption of cardioverter defibrillators and other active implantable devices in near to treat and improve the efficacy of the therapy, thereby expected to drive the active implantable devices market.
The report provides meticulous analysis of active implantable devices market on the basis of product type [implantable cardioverter defibrillators (transvenous ICDs and subcutaneous ICDs), neuromodulators (spinal cord stimulators, deep brain stimulators, sacral nerve stimulators, vagus nerve stimulators, and gastric electrical stimulators), implantable cardiac pacemakers, implantable hearing devices, ventricular assist devices, implantable heart monitors/insertable loop recorders], and geography.
This report is available at up to 20% discount for a limited time only: Enquire Before Buying
The key players analyzed in the active implantable devices market are Medtronic plc (Ireland), Abbott Laboratories (U.S.), and Boston Scientific Corporation (U.S.) together holding around three-fourth share of this market in 2016. The other key players in the global active implantable devices market are BIOTRONIK SE & Co. KG (Germany), and LivaNova PLC (U.K.), Cochlear Limited (Australia), MED-EL (Austria), Sonova Holding AG (Switzerland), William Demant Holding A/S (Denmark), and Nurotron Biotechnology Co., Ltd. (China).
Key Topics Covered in This Report:
- Research Methodology
- Executive Summary
- Market Share Analysis
- Market Insights
- Global Active Implantable Devices Market, By Products
- Geographic Analysis
- Competitive Landscape
- Company Profiles